BR112023022485A2 - Expansão de linfócitos em um único recipiente - Google Patents

Expansão de linfócitos em um único recipiente

Info

Publication number
BR112023022485A2
BR112023022485A2 BR112023022485A BR112023022485A BR112023022485A2 BR 112023022485 A2 BR112023022485 A2 BR 112023022485A2 BR 112023022485 A BR112023022485 A BR 112023022485A BR 112023022485 A BR112023022485 A BR 112023022485A BR 112023022485 A2 BR112023022485 A2 BR 112023022485A2
Authority
BR
Brazil
Prior art keywords
single container
cells
lymphocytes
lymphocyte expansion
expansion
Prior art date
Application number
BR112023022485A
Other languages
English (en)
Portuguese (pt)
Inventor
Alexandre Harari
Florence Salmon
George Coukos
Simone Steiner
Original Assignee
Centre Hospitalier Univ Vaudois Chuv
Ludwig Inst For Cancer Res Ltd
Tigen Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Hospitalier Univ Vaudois Chuv, Ludwig Inst For Cancer Res Ltd, Tigen Pharma Sa filed Critical Centre Hospitalier Univ Vaudois Chuv
Publication of BR112023022485A2 publication Critical patent/BR112023022485A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/13—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4201—Neoantigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/98—Xeno-free medium and culture conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2312—Interleukin-12 (IL-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1107—B cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2511/00—Cells for large scale production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
BR112023022485A 2021-04-30 2022-04-29 Expansão de linfócitos em um único recipiente BR112023022485A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21171565 2021-04-30
PCT/EP2022/061639 WO2022229464A1 (en) 2021-04-30 2022-04-29 Single vessel expansion of lymphocytes

Publications (1)

Publication Number Publication Date
BR112023022485A2 true BR112023022485A2 (pt) 2024-01-09

Family

ID=76034406

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023022485A BR112023022485A2 (pt) 2021-04-30 2022-04-29 Expansão de linfócitos em um único recipiente

Country Status (10)

Country Link
US (1) US20240287454A1 (https=)
EP (1) EP4330380A1 (https=)
JP (1) JP2024517793A (https=)
KR (1) KR20240026905A (https=)
CN (1) CN117321189A (https=)
AU (1) AU2022267777A1 (https=)
BR (1) BR112023022485A2 (https=)
CA (1) CA3214450A1 (https=)
MX (1) MX2023012698A (https=)
WO (1) WO2022229464A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115558641B (zh) * 2022-11-14 2023-05-12 四川新生命干细胞科技股份有限公司 高纯度效应免疫细胞群及其培养方法、试剂组合物和应用
WO2024261339A1 (en) 2023-06-23 2024-12-26 Tigen Pharma Sa Lymphocyte-stimulatory matrix (lsm) and uses thereof for expansion of lymphocyte populations

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
CU23734A1 (es) 2009-11-27 2011-11-15 Centro Inmunologia Molecular Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas
EP2569633B1 (en) 2010-05-14 2016-02-10 The General Hospital Corporation Compositions and methods of identifying tumor specific neoantigens
EP2983702A2 (en) 2013-04-07 2016-02-17 The Broad Institute, Inc. Compositions and methods for personalized neoplasia vaccines
US20160310584A1 (en) 2013-12-06 2016-10-27 The Broad Institute Inc. Formulations for neoplasia vaccines
KR20230076867A (ko) 2013-12-20 2023-05-31 더 브로드 인스티튜트, 인코퍼레이티드 신생항원 백신과의 병용 요법
EP3234130B1 (en) 2014-12-19 2020-11-25 The Broad Institute, Inc. Methods for profiling the t-cell- receptor repertoire
IL294183B2 (en) 2015-05-20 2023-10-01 Dana Farber Cancer Inst Inc shared neoantigens
EP3323070B1 (en) 2015-07-14 2024-05-08 Personal Genome Diagnostics Inc. Neoantigen analysis
ES2970865T3 (es) 2015-12-16 2024-05-31 Gritstone Bio Inc Identificación, fabricación y uso de neoantígenos
CA3034452A1 (en) 2016-08-21 2018-03-01 Adva Biotechnology Ltd. Bioreactor and methods of use thereof
WO2018213803A1 (en) 2017-05-19 2018-11-22 Neon Therapeutics, Inc. Immunogenic neoantigen identification
EP3707245A1 (en) * 2017-11-06 2020-09-16 Ludwig Institute for Cancer Research Ltd Method for expansion of lymphocytes
US20230052157A1 (en) 2019-12-12 2023-02-16 Achilles Therapeutics Uk Limited Method for obtaining nucleic acid for sequencing
JP2023510950A (ja) 2020-01-20 2023-03-15 アドヴァ バイオテクノロジー リミテッド バイオリアクタを制御する装置及び方法

Also Published As

Publication number Publication date
CA3214450A1 (en) 2022-11-03
JP2024517793A (ja) 2024-04-23
MX2023012698A (es) 2024-02-21
WO2022229464A1 (en) 2022-11-03
US20240287454A1 (en) 2024-08-29
EP4330380A1 (en) 2024-03-06
AU2022267777A1 (en) 2023-10-05
KR20240026905A (ko) 2024-02-29
CN117321189A (zh) 2023-12-29

Similar Documents

Publication Publication Date Title
BR112023022485A2 (pt) Expansão de linfócitos em um único recipiente
Gu et al. Synchronization for fractional-order discrete-time neural networks with time delays
AR069956A1 (es) Procesos para cultivar celulas mamiferas secretoras de proteinas sanguineas heterologas
BR112022003604A2 (pt) Produção de oligossacarídeos sialilados em células de bacillus
BR112023025137A2 (pt) Suporte para conter uma pluralidade de recipientes, peça em bruto para formar um suporte para conter uma pluralidade de recipientes, método para formar um suporte para conter uma pluralidade de recipientes, e pacote
BR112016020009A2 (pt) anticorpo, composição farmacêutica, método para inibir a proliferação de células cancerígenas, hibridoma
WO2023081412A3 (en) Immune cell populations and uses thereof
BR112023025136A2 (pt) Suporte para conter uma pluralidade de recipientes, peça em bruto para formar um suporte para conter uma pluralidade de recipientes, método para formar um suporte para conter uma pluralidade de recipientes, e embalagem
EP4462436A3 (en) Multiplex drop-off digital polymerase chain reaction methods
BR112021026002A2 (pt) Regeneração e transformação melhorada de plantas com a ajuda de um gene de reforço grf1
BR112023004023A2 (pt) Composição isolada, e, métodos para expandir linfócitos não limitados ao mhc não ¿d+ e para preparar uma composição, população de células enriquecida
BR112016023823A2 (pt) método para produção de um produto de fermentação
WO2022047222A3 (en) Crispr/cas9 multiplex knockout of host cell proteins
MX2021015698A (es) Integración dirigida de configuraciones aleatorias de ácidos nucleicos.
BR112022002765A2 (pt) Métodos para cultura de células
BR112023012510A2 (pt) Método para a fabricação de um objeto e folha revestida
BR112022016006A2 (pt) Cepas de produção dependentes de carga
MX2025008293A (es) Métodos de producción de linfocitos t gamma delta
BR112021020950A2 (pt) Extrato de levedura rico em trealose
Lwoff Introduction to biochemistry of protozoa
BR112023020542A2 (pt) Cepa de levedura saccharomyces, derivada de uma cepa de levedura saccharomyces, métodos de produção da derivada de uma cepa de levedura saccharomyces, da levedura mutante, da levedura evoluída e de um produto de fermentação a partir de um substrato, leveduras mutante, evoluída, geneticamente modificada e recombinante de uma cepa de levedura, processos para a produção de etanóis a partir de um substrato e de uma biomassa, e, composição
MX2021006330A (es) Portador de articulos y plantilla para el mismo.
CO2023015121A2 (es) Nuevo método
CO2023018654A2 (es) Método para producir linfocitos citolíticos naturales a partir de células madre pluripotentes
BR112023018940A2 (pt) Célula hospedeira geneticamente modificada capaz de produzir vanilina ou glucovanilina, método para produzir vanilina ou glucovanilina, e, vanilina ou glucovanilina

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]